Literature DB >> 25432591

Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication.

Reginald St Hilaire1, Heather Costello2.   

Abstract

Entities:  

Year:  2014        PMID： 25432591     DOI： 10.1016/j.ajem.2014.09.039

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN： 0735-6757            Impact factor:   2.469


× No keyword cloud information.
  5 in total

1.  Nonconvulsive Status Epilepticus in Elderly Patients Receiving SSRIs; Euglycemic Diabetic Ketoacidosis Associated with Canagliflozin Use in a Type 1 Diabetic Patient; Duloxetine-Induced Galactorrhea; Canagliflozin-Associated Severe Hypercalcemia and Hypernatremia; Vemurafenib-Induced Fanconi Syndrome.

Authors:  Michael A Mancano
Journal:  Hosp Pharm       Date:  2015-10-14

Review 2.  SGLT2 Inhibitors May Predispose to Ketoacidosis.

Authors:  Simeon I Taylor; Jenny E Blau; Kristina I Rother
Journal:  J Clin Endocrinol Metab       Date:  2015-06-18       Impact factor: 5.958

3.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.

Authors:  Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch
Journal:  Diabetes Care       Date:  2015-06-15       Impact factor: 19.112

Review 4.  Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.

Authors:  Awadhesh Kumar Singh
Journal:  Indian J Endocrinol Metab       Date:  2015 Nov-Dec

Review 5.  Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury.

Authors:  Michał Wiciński; Eryk Wódkiewicz; Karol Górski; Maciej Walczak; Bartosz Malinowski
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.